Two major federal contracts landed this week, putting $3 billion in government spending directly into the hands of publicly traded companies. While the bulk of the week's signals involved state-level grants and private entities, two clear public beneficiaries emerged: $MRK (Merck) and $SAIC (Science Applications International Corporation). Here's what traders need to know about these awards and why they matter for your portfolio.
The $2.4B Merck Vaccine Contract
Merck & Co. ($MRK) secured a $2.4B indefinite delivery/indefinite quantity contract from the CDC for the Vaccines for Children program for fiscal year 2025. This is a routine renewal of a longstanding federal program that provides vaccines to children, reinforcing Merck's dominant position in pediatric vaccines. The contract represents roughly 4% of Merck's annual revenue, providing stable, government-backed cash flow.
While not a growth catalyst, it adds visibility to Merck's top line and reduces downside risk.